ArticleESC heart failure2022

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.

Lars H Lund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.